Fulgent Genetics, Inc. Selected for Rapid Oral Presentation in Head & Neck Cancer Track at ASCO Annual Meeting 2026 Fulgent Genetics, Inc., a technology-driven company known for its established laboratory services and expanding therapeutic development pipeline, announced that one of…
Definium Therapeutics Showcases DT120 ODT (Lysergide Tartrate) Progress and Commercial Plans at Investor & Analyst Day Definium Therapeutics, a late-stage clinical biopharmaceutical company, recently provided a comprehensive update on the progress of its lead investigational therapy, DT120 ODT (lysergide tartrate),…
Federal Push Accelerates Psychedelic Therapies as Clinical Infrastructure Races to Keep Up The landscape of mental health treatment development is undergoing a significant transformation as recent federal action signals a stronger commitment to accelerating psychedelic therapies through the regulatory pipeline.…
Treehub by AI Health Fund Launches to Identify Next-Generation Academic and Scientific Founders Treehub, a newly launched Stanford-adjacent residency backed by the AI Health Fund, is positioning itself as a transformative force in healthcare innovation by identifying and supporting early-stage…
Kallyope Reports Promising Phase 2b Results for Elismetrep, Introducing a Novel Mechanism for Acute Migraine Treatment Kallyope, a late-stage biotechnology company dedicated to developing innovative therapies for neurological and metabolic disorders, has announced encouraging results from its Phase 2b clinical…
Ten IVI RMA North America Clinics Ranked Among Newsweek’s 2026 America’s Best Fertility Clinics IVI RMA North America, a leading provider of fertility care and assisted reproductive technologies, has announced that ten clinics within its expansive national network have been…
CareDx Showcases 50+ Abstracts, 16 Oral Talks at ISHLT 2026 CareDx has announced its participation in the International Society for Heart and Lung Transplantation 46th Annual Meeting (ISHLT 2026), taking place from April 22 to 25 in Toronto, Canada. The…
Avenzo Therapeutics to Present New Phase 1 Data on AVZO-021 (CDK2 Inhibitor) at the 2026 American Society of Clinical Oncology Annual Meeting Avenzo Therapeutics has announced a significant milestone in its ongoing efforts to develop innovative cancer therapies, revealing that…
Community Health Systems, Inc. Reports First Quarter 2026 Financial Results Community Health Systems has announced its financial and operational performance for the first quarter ending March 31, 2026, highlighting both ongoing challenges and strategic progress in a complex healthcare environment.…
Assertio Evaluates Alternatives as Acquisition Process Moves Forward Assertio Holdings, has provided an important update regarding its ongoing acquisition process involving Garda Therapeutics, The announcement, distributed via Business Wire, outlines key developments tied to a previously disclosed agreement between the…
From IVF Science to Skin Longevity: AV Laboratories Turns Biotechnology into Breakthrough Skincare AV Laboratories is reshaping the skincare landscape by bringing decades of advanced biotechnology research into everyday beauty routines. Drawing on deep expertise in in vitro fertilization (IVF)…
Synthekine Reports Updated Clinical and Translational Findings for STK-012 in First-Line Non-Squamous NSCLC at AACR 2026 Synthekine, a clinical-stage biotechnology company focused on precision cytokine therapeutics, has released updated clinical and translational data for its investigational therapy STK-012. The results…